NORTHLAND(BJ:430047)2023-09-11 10:44Group 1: Research Overview - The company received 34 institutional investor inquiries on September 7, 2023 [1][3] - The research was conducted online with participation from various fund management companies and securities firms [3] Group 2: Clinical Trial Progress - The clinical trial for NL003 has completed all patient enrollments and is expected to finish follow-ups by December 2023, with statistical analysis and registration document preparation planned for Q2 2024 [4] - The clinical trial for resting pain is scheduled to complete all subject enrollments within 2023, followed by a 6-month follow-up period [4] Group 3: Commercialization Status - The company is actively preparing for the commercialization of NL003, collaborating with IQVIA for comprehensive product and market research [5][6] - The commercialization strategy will consider market factors such as product characteristics, value positioning, regional markets, insurance pathways, and sales strategies [6] Group 4: Treatment Insights - Approximately 50% of patients currently undergo interventional surgery, but only about 25% achieve a cure, with high recurrence rates [6] - NL003 aims to address the market gaps left by surgical interventions, particularly for patients who cannot undergo surgery and to expand applications to mild indications [6] Group 5: Mechanism of Action - NL003's mechanism is focused on improving microcirculation, specifically enhancing blood supply in small vessels and vascular networks [7] - The company is conducting exploratory trials with Peking Union Medical College Hospital to evaluate the drug's angiogenic effects using imaging techniques [7] Group 6: Patient Outcomes - ABI (Ankle-Brachial Index) and TBI (Toe-Brachial Index) are auxiliary diagnostic measures but are not definitive indicators of treatment efficacy [8] - The treatment with NL003 is less invasive compared to existing surgical options, potentially improving patient compliance, especially among elderly and comorbid patients [8] Group 7: Injection Site Selection - The selection of injection sites for NL003 will involve angiography, as blockage locations vary among patients, with recommendations for typical injection sites to follow [8]